Showing posts with label Musella_Foundation. Show all posts
Showing posts with label Musella_Foundation. Show all posts

Monday, 28 October 2019

Musella yahoo groups shutting down. New forum address

Here is a message from Al Musella.  Please check out and support his new forum.

This group is closing down as Yahoo no longer will provide groups. We are moving to forum.virtualtrials.org 
Please register there and try it out!

Monday, 11 September 2017

Treatment Options for Glioblastoma and Other Gliomas - 2017 edition

This is the in-depth summary of treatment options that Ben Williams began years ago, and which I have taken over lately.  Download the 2017 update over at virtualtrials.com  , or click here for PDF download.   This can be discussed on Al Musella's BrainTumorTreatments yahoo group .  (Of course comments welcome here as well).

Monday, 16 January 2017

From Musella's website: Immunotherapies for GBM: Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A.

Immunotherapies for GBM: Tumor Vaccines by Linda Liau, M.D., Ph.D., M.B.A.         This is a video about the DCVax trial, given by one of my all time favorite brain tumor doctors, Dr. Liau.  This looks very promising. We are hoping to hear the results of the big phase 3 trial soon.  In the earlier trials and in the early progressors which were excluded from this trial but were followed as they took the vaccine,  about 25% of the patients went on to be long term survivors, with many alive and progression free 5-10 years later.  That is unheard of with the standard treatments. Some other immunotherapies have also reported similiar results (although not as long follow up).    We are hoping this large phase 3 trial shows something close to that so it can be approved quickly and all patients can benefit from it.  Best of all it had no serious side effects. Dr. Liau is on the Musella Foundation Medical Advisory Board.  The Musella Foundation has supported Dr Liau's immunotherapy research with $375,000 in grants and we have never received any financial  support from the company developing this treatment, Northwest Biotherapeutics.